Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Lancet Infect Dis ; 15(9): 1017-1023, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26116183

RESUMO

BACKGROUND: The ongoing west Africa Ebola-virus-disease epidemic has disrupted the entire health-care system in affected countries. Because of the overlap of symptoms of Ebola virus disease and malaria, the care delivery of malaria is particularly sensitive to the indirect effects of the current Ebola-virus-disease epidemic. We therefore characterise malaria case management in the context of the Ebola-virus-disease epidemic and document the effect of the Ebola-virus-disease epidemic on malaria case management. METHODS: We did a cross-sectional survey of public health facilities in Guinea in December, 2014. We selected the four prefectures most affected by Ebola virus disease and selected four randomly from prefectures without any reported cases of the disease. 60 health facilities were sampled in Ebola-affected and 60 in Ebola-unaffected prefectures. Study teams abstracted malaria case management indicators from registers for January to November for 2013 and 2014 and interviewed health-care workers. Nationwide weekly surveillance data for suspect malaria cases reported between 2011 and 2014 were analysed independently. Data for malaria indicators in 2014 were compared with previous years. FINDINGS: We noted substantial reductions in all-cause outpatient visits (by 23 103 [11%] of 214 899), cases of fever (by 20249 [15%] of 131 330), and patients treated with oral (by 22 655 [24%] of 94 785) and injectable (by 5219 [30%] of 17 684) antimalarial drugs in surveyed health facilities. In Ebola-affected prefectures, 73 of 98 interviewed community health workers were operational (74%, 95% CI 65-83) and 35 of 73 were actively treating malaria cases (48%, 36-60) compared with 106 of 112 (95%, 89-98) and 102 of 106 (96%, 91-99), respectively, in Ebola-unaffected prefectures. Nationwide, the Ebola-virus-disease epidemic was estimated to have resulted in 74 000 (71 000-77 000) fewer malaria cases seen at health facilities in 2014. INTERPRETATION: The reduction in the delivery of malaria care because of the Ebola-virus-disease epidemic threatens malaria control in Guinea. Untreated and inappropriately treated malaria cases lead to excess malaria mortality and more fever cases in the community, impeding the Ebola-virus-disease response. FUNDING: Global Fund to Fight AIDS, Tuberculosis and Malaria, and President's Malaria Initiative.


Assuntos
Centros Comunitários de Saúde/estatística & dados numéricos , Atenção à Saúde/estatística & dados numéricos , Epidemias , Doença pelo Vírus Ebola/epidemiologia , Hospitais/estatística & dados numéricos , Malária/tratamento farmacológico , Adolescente , Adulto , Antimaláricos/uso terapêutico , Criança , Pré-Escolar , Estudos Transversais , Feminino , Febre/tratamento farmacológico , Febre/parasitologia , Guiné/epidemiologia , Humanos , Malária/complicações , Aceitação pelo Paciente de Cuidados de Saúde/estatística & dados numéricos , Cuidado Pré-Natal/estatística & dados numéricos , Adulto Jovem
2.
Lancet ; 359(9318): 1667-8, 2002 May 11.
Artigo em Inglês | MEDLINE | ID: mdl-12020529

RESUMO

Most people who have HIV-1 and live in less-developed countries cannot afford standard combination antiretroviral therapy, and more economical approaches to treatment are therefore needed. We treated 22 patients who were infected with HIV-1 (viral load < 100000 copies/mL and CD4 count >150 cells/microL) with hydroxychloroquine (200 mg), hydroxycarbamide (hydroxyurea) (500 mg), and didanosine (125-200 mg), taken twice daily. Treatment was well tolerated, with few serious adverse events. Viral load showed a sustained decrease of 1 3 log, and CD4 count was maintained (percentage increase; 2 9%) over 48 weeks in the 16 evaluable patients. This new combination of drugs could be suitable for countries that have restricted resources, but should first be further investigated.


Assuntos
Fármacos Anti-HIV/uso terapêutico , Didanosina/uso terapêutico , Inibidores Enzimáticos/uso terapêutico , Infecções por HIV/tratamento farmacológico , HIV-1 , Hidroxicloroquina/uso terapêutico , Hidroxiureia/uso terapêutico , Adulto , Fármacos Anti-HIV/economia , Contagem de Linfócito CD4 , Didanosina/economia , Quimioterapia Combinada , Inibidores Enzimáticos/economia , Feminino , Humanos , Hidroxicloroquina/economia , Hidroxiureia/economia , Masculino , Projetos Piloto , Resultado do Tratamento , Carga Viral
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA